imsidolimab
imsidolimab: sourced relationships with 1 company · 7 clinical trials tracked.
imsidolimab evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could imsidolimab → ANAB affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ANAPTYSBIO, INC (ANAB) | BLA Filed |
Clinical Trial Registry Records (7)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
Primary endpoint: Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
Primary endpoint: Change From Baseline in AN Count at Week 16: Placebo-Controlled Period
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Primary endpoint: Change From Baseline in Facial Inflammatory Lesion Counts at Week 12
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects With Neoplasm Receiving EGFRi or MEKi Therapy
Primary endpoint: Change From Baseline in Facial Inflammatory Lesion Count (Papules and Pustules) at Week 8
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis
Primary endpoint: Change From Baseline in Ichthyosis Area Severity Index (IASI) Total Score at Week 16
A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
Primary endpoint: Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI)
A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
Primary endpoint: Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale
Frequently asked questions
Which companies have sourced relationships with imsidolimab?
imsidolimab has dated SEC/FDA relationship records for ANAPTYSBIO, INC.
How many clinical trials involve imsidolimab?
BioSniper tracks 7 clinical trials involving imsidolimab.